Nature Reviews Drug Discovery

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2298
Vaccine exposes tumours to immune cell attack	1342
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	880
The importance of persistence in cancer drug development	756
A specific biomarker for insoluble tau	737
Targeting tumour-associated bacteria	592
A new path to targeted protein degradation?	566
Neutralizing Zika virus	560
The improving benefit–risk balance of phase I cancer trials	548
FDA approves a c-MET-targeted ADC for lung cancer	515
Tumour cells get a dendritic cell makeover	494
Glucose-sensitive insulin protects against hypoglycaemia	468
Promoting tissue repair after heart attack	454
mRNA-encoded monoclonal antibody fights CHIKV	424
Hypoimmune iPSCs escape immune detection	405
Lipid nanoparticle ferries therapeutic mRNA to the placenta	362
Targeting drug-resistant glioblastoma	353
FDA new drug approvals in Q1 2023	335
Apolipoprotein L2 inhibitor mitigates fibrosis	334
Chemical engineering of CRISPR–Cas systems for therapeutic application	315
Degrading cell-free DNA to prevent recurrent stroke	314
FDA approves second TTR stabilizer for cardiac amyloidosis	294
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	290
Top companies and drugs by sales in 2021	290
New antibiotic for urinary tract infections nabs FDA approval	288

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	279
Anti-tau antibody stumbles in phase II Alzheimer trial	273
Small-molecule discovery through DNA-encoded libraries	262
Evolution of innovative drug R&D in China	255
2022 FDA approvals	243
mRNA vaccines for infectious diseases — advances, challenges and opportunities	242
Targeting the Hippo pathway in cancer	231
Increasing the potency of T cell therapies	229
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	229
Small molecule improves muscle function in myasthenia gravis	228
Blocking breast cancer metastasis	216
Pushing both sides of the drug pricing aisle	200
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	200
Host-directed antiviral blocks SARS-CoV-2 entry	195
TCR-engineered T cells get personal	194
FDA new drug approvals in Q2 2023	183
Inhibiting ASGR1 boosts cholesterol removal	180
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	173
Rewired proteostasis in KRAS inhibitor resistance	173
R&D re-balancing act	169
A call to action for translational sciences in COVID-19 and future pandemics	159
Mimicking the health benefits of exercise	155
Screening ultra-large virtual libraries	155
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	155
FDA approves second BCMA-targeted CAR-T cell therapy	153
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	149
Reflections on 10 years of the FDA’s breakthrough therapy designation	144
Pan-coronavirus vaccine pipeline takes form	142
Phenotypic drug discovery: recent successes, lessons learned and new directions	141
The antibody–drug conjugate landscape	140
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	138
Combating antimicrobial resistance in malaria, HIV and tuberculosis	130
Base editors hit the clinic	125
Amylin takes another shot at the obesity prize	120
The significance of blockbusters in the pharmaceutical industry	114
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	112
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	108
The emerging role of mass spectrometry-based proteomics in drug discovery	105
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	105
Multi-TACs target solid tumours	104
Antibody–drug conjugates come of age in oncology	104
Immunology on the brain	103
Gut metabolite mediates nerve repair	99
Reducing IL-2 toxicity	98
Agonist antibody lowers blood pressure	95
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	93
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	91
Monkeypox mRNA vaccine protects mice and macaques	91
Neglected tropical diseases go global	89
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	87

GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	85
Anti-IL-11 antibody shows anti-ageing properties	85
Ribosome inhibitor combats bacterial drug resistance	84
The malignant melanoma market	83
LRRK2-targeted Parkinson disease drug advances into phase III	82
Frameworks for transformational breakthroughs in RNA-based medicines	80
Targeting the ECM in melanoma	80
The European Innovation Network as a hub for medicines innovation in Europe	77
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	76
Avidity in antibody effector functions and biotherapeutic drug design	73
Engineering a compact genome-editing tool	72
Engineered parasite delivers proteins to the brain	72
RNA structure guides antiviral ASO design	70
Delivering genome editing tools to primary cells	70
Covalent inhibitor engages oncogenic AKT kinase	69
Upcoming market catalysts in Q4 2023	69
A rush of CRISPR to the lungs	68
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	68
Publisher Correction: Roflumilast	66
Broader horizons for cereblon glue degraders	65
FDA approves first PSMA-targeted radiopharmaceutical	65
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	63
Trends in the development of cellular and gene therapy in China	57
Promoting efferocytosis heals diabetic wounds	56
Accelerating precision oncology by converging pragmatic trials and real-world evidence	53
The non-small-cell lung cancer drug market	52
Targeting protein disorder: the next hurdle in drug discovery	52
MYC in cancer: from undruggable target to clinical trials	51
Investigating the origins of recent pharmaceutical innovation	49
AAV-based in vivo gene therapy for neurological disorders	49
Identification of neoantigens for individualized therapeutic cancer vaccines	46
Three-step cures for autoimmune diseases?	45
A bacteria-derived oral tumour vaccine	45
V-ATPase inhibitor targets Ras-mutant cancers	42
RNA delivery heats up cold tumours	42
Upcoming market catalysts in Q4 2024	41
Can large, simple trials bring drug developers back to common diseases?	40
Designing novel macrocyclic drugs	40
Towards a broad-spectrum antiviral agent	39
Microbial ‘dark matter’ yields new antibiotic	38
The case for cell-penetrating peptides	37
Analysis of China-to-West pharmaceutical licensing deals in 2024	37
The evolution of the obesity drug market	37
Understanding LAG3 immune checkpoint function	36
De novo design of macrocycles	36
Neurotensin receptor modulator safely tackles pain	36
FDA approves cell-sheet-based gene therapy for severe skin disease	35
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	33
Hinge modifier approach opens door to drugging HECT E3 ligases	33
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	32
RNA chemistry and therapeutics	32
Glue-based KRAS inhibitors make their debut cancer trial mark	31
Novel strategies to manage CAR-T cell toxicity	31
The market for ulcerative colitis	30
2023 FDA approvals: unprecedented volume at moderate value	30
Therapeutically harnessing extracellular vesicles	30
A new drug target for NRAS(Q61) mutant-expressing cancers	30
PPAR agonists provide new treatment options for inflammatory liver disease	30
Cartilage regeneration for osteoarthritis	29
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	28
A faster route to antidepressant activity	27
Refining HIV pre-exposure prophylactic agents	27
Synthetic cytokine circuit targets solid tumours	27
Designing closure-stabilizing integrin inhibitors	26
Targeting sigma receptor 1 in long QT syndrome	26
Transcription reprogramming to enhance CAR-T cell function	26
miR-21 antagomir reverses COPD pathology	25
A step closer to in vivo editing of haematopoietic stem cells	25
Designing a novel synthetic receptor	25
Novel schizophrenia therapy filed for FDA approval	24
Enhancing CAR-T cell efficacy through IFN ablation	24
FDA approves first factor XIIa inhibitor, for hereditary angioedema	24
PD1 × VEGF blocking bispecifics for cancer draw big backing	24
In vivo CAR T cells move into clinical trials	23
FDA approves 21-valent pneumococcal vaccine	23
Sequential immunotherapy: towards cures for autoimmunity	22
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	22
Genome-editing medicinal products: the EMA perspective	22
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	21
FDA approves decades-old maribavir for CMV infection	21

Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	21
Improving efficacy of ASO therapy in SMA	21
Top product forecasts for 2025	20
CAR T cells take to the airways	20
Unmet needs in vaccine development	20
FDA approves PI3Kα inhibitor that does double duty as a degrader	20
Anti-histamines boost immunotherapy	20
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	19
Designing insulin receptor agonists	19
Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	19
Targeting galectin-driven regulatory circuits in cancer and fibrosis	18
Understanding the effects of antibiotic combinations	18
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety	18
RNAi-based drug design: considerations and future directions	18
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	18
Drugging the efferocytosis process: concepts and opportunities	18
Acyl-lysine reader inhibitor blocks AML progression	17
Treating cannabis use disorder	17
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	17
Synthesizing portimines	17
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	17
Bacteria tag tumours for CAR-T cell attack	16
Trustworthy AI for safe medicines	16
Stalled molecular motor inhibits tumour growth	16
Open-science drug discovery for COVID-19	16
Epigenetic editor silences prion protein	16
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	16
Brain glucose mediates amphotericin B tolerance	16
Neurons give metastatic cells a push	15
ASO targets DNA repair protein to combat Huntington disease	15
Bispecific antibodies in oncology	15
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	15
Building on the momentum of N-of-1 base editor therapies for rare diseases	15
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	15
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	15
Alnylam scores big pharma support for angiotensinogen silencer	14
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	14
opnMe.com: a digital initiative for sharing tools with the biomedical research community	14
Trends in the drug target landscape for autoimmune diseases	14
Advanced technologies for the development of infectious disease vaccines	14
Thinking outside the box: non-canonical targets in multiple sclerosis	14
The KRAS crowd targets its next cancer mutations	14
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	14
Insights into new approach methodology innovation: an EMA perspective	14
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	14
A type 1 regulatory T cell-based therapy	13
Gene editing addresses antithrombin deficiency	13
A new antibiotic for A. baumannii	13
Understanding sphingosine-1-phosphate transport	13
FDA releases tissue-agnostic cancer drug draft guidance	12
Ramping up mitochondrial DNA replication	12
Soluble Notch agonists drive T cell production	12
Understanding immunomodulatory antibody agonism	12
Hooking FSH as a potential target for Alzheimer disease	12
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	11
Upcoming market catalysts in Q3 2023	11
Targeting ALDH1B1 in colorectal cancer	11
Targeting cytokine networks in neuroinflammatory diseases	11
FDA approves first claudin-18.2-targeted antibody for gastric cancer	11
Setting GPCRs free	11
FDA approves first chikungunya vaccine	11
DUBTACs for targeted protein stabilization	11
FDA approves first two drugs for rare Niemann–Pick disease	11
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	11
Antibody cocktail eliminates ebolaviruses	10
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	10
Inhibiting metallo-β-lactamases	10
Targeting expanded trinucleotide repeats	10
The renal cell carcinoma drug market	10
Top product forecasts for 2022	10
Membrane transporters in drug development and as determinants of precision medicine	10
Two-pronged approach for macular degeneration	10
Phosphatase inhibitor drives anticancer immune responses	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	10
Macrophages as tools and targets in cancer therapy	10
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	10
New route to target RAS	9
Repurposing beta-blockers in breast cancer	9
Targeting ephrin signalling in sepsis	9
Antibody drug conjugate combats inflammation	9
New therapeutic candidate for Chagas disease	9
Mapping cysteine ligandability	9
Chromatin-targeted drug discovery at “a very special moment”	9
BacPROTAC to treat tuberculosis	9
mRNA vaccine for Lyme disease prevention	9
Antibody–oligonucleotide conjugates enter the clinic	8
Developing an IKZF2 glue degrader	8
How multispecific molecules are transforming pharmacotherapy	8
2022 FDA approval number dips: a COVID-19 hangover?	8
The potential of innovative trial design for efficiently evaluating repurposed drugs	8